Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Effect of the GABAB agonist baclofen on symptoms of GERD

The GABAB agonist baclofen reduces 24 hour gastro-esophageal reflux and increases gastric pH in patients with GERD, finds a research team in the April issue of Gut.

News image

The gamma-aminobutyric acid (GABAB) agonist baclofen reduces reflux episodes in the first 3 postprandial hours. This occurs in both patients with gastro-esophageal reflux disease (GERD) and in normal controls.

In this study, researchers from Italy assessed acute and chronic administration of baclofen on 24-hour pH metry and symptoms in GERD patients and normal controls.

In the acute study, the team assessed 28 patients with GERD, and none or mild esophagitis at endoscopy. They also assessed 15 controls.

Baclofen or placebo were administered for 24 hours in a double blinded manner.

In the acute study, gastric pH increased significantly in both groups.
Gut

Subjects underwent esophageal and gastric 48-hour pH metry.

In the chronic study, 16 GERD patients received baclofen (10 mg 4 times daily) or placebo for 4 weeks.

The team evaluated 24-hour esophageal pH metry and reflux symptom scores before and after treatment.

In the acute study, researchers found that the number of reflux episodes and percent of time with pH < 4 was significantly lower after baclofen in both GERD patients and controls.

In addition, gastric pH increased significantly in both groups.

In the chronic study, the team found that 4 weeks after initial administration of baclofen, the number of reflux episodes and percentage of time with pH < 4 significantly decreased in all GERD patients.

In addition, symptom scores significantly improved after treatment with baclofen.

Profs. Ciccaglione and Marzio concluded, "The GABAB agonist baclofen reduces 24 hour gastro-esophageal reflux and increases gastric pH in GERD patients and controls".

"When given for 1 month to GERD patients, baclofen reduces esophageal acid refluxes and significantly improves symptoms."

"Baclofen may be useful in the therapy of GERD."

Gut 2003; 52: 464-70
14 March 2003

Go to top of page Email this page Email this page to a colleague

 15 September 2014

Advanced search
 15 September 2014 
Antidepressants for IBS
 15 September 2014 
Prunes and GI function
 15 September 2014 
Fecal transplantation for C.diff infection
 12 September 2014 
Management of complex colon polyps
 12 September 2014 
Metabolic syndrome delays HBeAg seroclearance
 12 September 2014 
Drug-induced liver disease
 11 September 2014 
Hepatobiliary cirrhosis risk after organ transplant
 11 September 2014 
Sofosbuvir plus peginterferon/ribavirin for HCV
 11 September 2014 
Patient perceptions in celiac disease
 10 September 2014 
Adhesions in abdominal and pelvic surgery
 10 September 2014 
Acute kidney injury after colonoscopy
 10 September 2014 
Management algorithm for endoscopic mucosal resection of colonic lesions
 09 September 2014 
PPIs and spontaneous bacterial peritonitis in cirrhosis
 09 September 2014 
Neutrophil function and mortality in cirrhosis
 09 September 2014 
MELD and liver cancer survival
 08 September 2014 
Vagal nerve blockade and morbid obesity
 08 September 2014 
Comparison of diet programs in overweight and obese adults
 08 September 2014 
Long-term follow-up after bariatric surgery
 05 September 2014 
Healing rates in reflux esophagitis
 05 September 2014 
Progression of environmental enteropathy
 05 September 2014 
Diabetes and liver transplant outcomes
 04 September 2014 
Colectomy rates for refractory ulcerative colitis
 04 September 2014 
Infliximab prevents long-term Crohn’s disease recurrence
 04 September 2014 
Histological recovery with gluten-free diet in celiac disease
 03 September 2014 
Diagnosis of atrophic gastritis
 03 September 2014 
Predictors of response in Crohn's disease
 03 September 2014 
Safety of reinitiation of infliximab therapy
 02 September 2014 
SSRIs and depression in Hep C
 02 September 2014 
Bariatric surgery for obesity
 02 September 2014 
Eosinophilic esophagitis in adults
 01 September 2014 
Risks with anti-TNF in pediatric IBD
 01 September 2014 
Genetic variants in alcoholic liver disease
 01 September 2014 
Fecal hemoglobin and colorectal cancer screening
 29 August 2014 
Gluten-free diet for asymptomatic celiac disease
 29 August 2014 
NSAID-induced small intestinal injury and diaphragm disease
 29 August 2014 
Symptom evaluation in functional dyspepsia
 28 August 2014 
Predictoris of C. diff in out-patients
 28 August 2014 
Detection of gastroesophageal reflux symptoms
 28 August 2014 
Colorectal-cancer mortality after adenoma removal
 27 August 2014 
Endoscopy outcomes in community hospital vs tertiary academic centers
 27 August 2014 
UV exposure and IBD hospitalizations
 27 August 2014 
Hepatocellular carcinoma screening in liver disease
 26 August 2014 
NAFLD and gastroesophageal reflux symptoms
 26 August 2014 
Adalimumab-treated patients with ulcerative colitis
 26 August 2014 
Wound healing after abdominoperineal resection
 25 August 2014 
Surgical management of rectourethral fistulas
 25 August 2014 
Biomarker analysis in biopsies for ulcerative colitis
 25 August 2014 
Ileocolic resection in Crohn's disease
 22 August 2014 
Outlier identification in colorectal surgery
 22 August 2014 
Endoscopic submucosal dissection for squamous esophageal cancer
 22 August 2014 
Adherence to Rome criteria in functional dyspepsia trials
 21 August 2014 
Screening for Barrett’s esophagus
 21 August 2014 
Colorectal cancer mortality in Brazil
 21 August 2014 
Eosinophilic esophagitis
 20 August 2014 
Rectal surgery mortality
 20 August 2014 
Chemotherapy-induced gastrointestinal mucositis
 20 August 2014 
Stool methylated DNA markers and colorectal cancer resection
 19 August 2014 
Recurrent C. difficile infection in out-patients
 19 August 2014 
Racial disparities and colon cancer
 19 August 2014 
Variability of colonoscopy preparation instructions

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us